$DARE
Dare Bioscience, Inc.

2019 Q1 Form 10-K Financial Statement

#000140191419000015 Filed on April 01, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.390M $1.300M $980.0K
YoY Change -0.71% 32.65% 415.79%
% of Gross Profit
Research & Development $1.693M $1.660M $670.0K
YoY Change 55.84% 147.76% -78.96%
% of Gross Profit
Depreciation & Amortization $1.150K $0.00
YoY Change
% of Gross Profit
Operating Expenses $3.083M $2.960M $1.650M
YoY Change -59.84% 79.39% -68.71%
Operating Profit -$3.083M
YoY Change -59.84%
Interest Expense $10.00K
YoY Change -97.81%
% of Operating Profit
Other Income/Expense, Net $31.23K $40.00K
YoY Change 165.93%
Pretax Income -$3.050M -$2.920M -$9.130M
YoY Change -60.23% -68.02% 4465.0%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.052M -$2.920M -$9.130M
YoY Change -60.19% -68.02% 84.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$267.1K -$255.5K -$1.502M
COMMON SHARES
Basic Shares Outstanding 11.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.510M $6.810M $7.560M
YoY Change -77.54% -9.92% 18800.0%
Cash & Equivalents $3.500M $6.806M $7.560M
Short-Term Investments
Other Short-Term Assets $590.0K $0.00 $193.5K
YoY Change 103.45% -100.0%
Inventory
Prepaid Expenses $588.5K $403.1K $311.6K
Receivables
Other Receivables $166.7K $31.04K $284.2K
Total Short-Term Assets $4.260M $7.240M $8.349M
YoY Change -73.28% -13.28% -77.31%
LONG-TERM ASSETS
Property, Plant & Equipment $8.245K $9.396K $0.00
YoY Change -100.0%
Goodwill $0.00 $5.200M
YoY Change -100.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $751.3K $578.0K $723.2K
YoY Change 8.89% -20.08% 5604.3%
Total Long-Term Assets $759.6K $587.4K $5.911M
YoY Change 10.86% -90.06% 558.21%
TOTAL ASSETS
Total Short-Term Assets $4.260M $7.240M $8.349M
Total Long-Term Assets $759.6K $587.4K $5.911M
Total Assets $5.020M $7.827M $14.26M
YoY Change -69.81% -45.11% -62.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $330.0K $459.7K $308.2K
YoY Change -59.26% 49.15% -78.68%
Accrued Expenses $690.8K $631.4K $658.4K
YoY Change -4.11% -85.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.016M $1.091M $966.7K
YoY Change 25.86% 12.87% 27.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $223.0K $9.711K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $223.0K $9.711K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.016M $1.091M $966.7K
Total Long-Term Liabilities $223.0K $9.711K $0.00
Total Liabilities $1.239M $1.101M $967.0K
YoY Change 52.93% 13.83% 28.05%
SHAREHOLDERS EQUITY
Retained Earnings -$32.02M -$28.97M -$12.23M
YoY Change 60.94% 136.86% 1580.46%
Common Stock $35.89M $35.79M $25.54M
YoY Change 0.4% 40.14% 148278.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.780M $6.727M $13.29M
YoY Change
Total Liabilities & Shareholders Equity $5.020M $7.827M $14.26M
YoY Change -69.82% -45.11% 31862.68%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2017 Q4
OPERATING ACTIVITIES
Net Income -$3.052M -$2.920M -$9.130M
YoY Change -60.19% -68.02% 84.63%
Depreciation, Depletion And Amortization $1.150K $0.00
YoY Change
Cash From Operating Activities -$3.308M -$2.710M -$960.0K
YoY Change 56.14% 182.29% 500.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 0.000 0.000
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -$3.308M -2.710M -960.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities $0.00 0.000 0.000
Net Change In Cash -$3.301M -2.710M -960.0K
YoY Change -140.93% 182.29% -2500.0%
FREE CASH FLOW
Cash From Operating Activities -$3.308M -$2.710M -$960.0K
Capital Expenditures $0.00
Free Cash Flow -$2.710M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dare Adjustments To Additional Paid In Capital Common Stock And Warrants Issued
AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssued
734235 USD
CY2017 dare Cash Acquired Through Reverse Merger
CashAcquiredThroughReverseMerger
9918440 USD
CY2018 dare Cash Acquired Through Reverse Merger
CashAcquiredThroughReverseMerger
0 USD
CY2018Q1 dare Class Of Warrant Or Right Conversion Of Common Stock
ClassOfWarrantOrRightConversionOfCommonStock
0.70
CY2018 dare Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
170 shares
CY2017Q4 dare Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
15176000 USD
CY2018Q4 dare Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
13334000 USD
CY2017Q4 dare Deferred Tax Assets Other Amortizable Costs
DeferredTaxAssetsOtherAmortizableCosts
3377000 USD
CY2018Q4 dare Deferred Tax Assets Other Amortizable Costs
DeferredTaxAssetsOtherAmortizableCosts
11000 USD
CY2017 dare Effective Income Tax Rate Reconciliation Goodwill Impairment
EffectiveIncomeTaxRateReconciliationGoodwillImpairment
-0.221
CY2018 dare Effective Income Tax Rate Reconciliation Goodwill Impairment
EffectiveIncomeTaxRateReconciliationGoodwillImpairment
-0.0648
CY2017 dare Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.028
CY2018 dare Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0031
CY2018Q4 dare Grant Funding Recognized During Period
GrantFundingRecognizedDuringPeriod
225000 USD
CY2018Q1 dare Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
11300000 USD
CY2017 dare License Fee
LicenseFee
0 USD
CY2018 dare License Fee
LicenseFee
625000 USD
CY2018 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0 shares
CY2018Q3 dare Operating Lease Rentable Area
OperatingLeaseRentableArea
3169 sqft
CY2017 dare Payments For Asset Acquisition
PaymentsForAssetAcquisition
0 USD
CY2018 dare Payments For Asset Acquisition
PaymentsForAssetAcquisition
507000 USD
CY2017Q4 dare Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
720391 USD
CY2018Q4 dare Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
562266 USD
CY2017 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
CY2018 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
10111952 USD
CY2017 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.00
CY2018 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.00
CY2017 dare Tax Cuts And Jobs Act Of2017 Incomplete Accounting Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit
23600000 USD
CY2017 dare Uncertain Tax Benefits Increase Resulting From Current Period Purchase Accounting
UncertainTaxBenefitsIncreaseResultingFromCurrentPeriodPurchaseAccounting
781000 USD
CY2018 dare Uncertain Tax Benefits Increase Resulting From Current Period Purchase Accounting
UncertainTaxBenefitsIncreaseResultingFromCurrentPeriodPurchaseAccounting
0 USD
CY2018Q4 dare Unremitted Earnings
UnremittedEarnings
0 USD
CY2018 dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P3Y3M22D
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001401914
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11422161 shares
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
10682000 USD
CY2018 dei Entity Registrant Name
EntityRegistrantName
Dare Bioscience, Inc.
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Trading Symbol
TradingSymbol
DARE
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
658434 USD
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
631351 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
308219 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
459705 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
658434 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
631351 USD
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
259600 USD
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
32457 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18080 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-96728 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
25541210 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35791972 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
316805 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15832 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
139348 USD
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15832 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
139348 USD
CY2017Q4 us-gaap Assets
Assets
14259828 USD
CY2018Q4 us-gaap Assets
Assets
7827387 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
8349118 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
7240023 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44614 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7559846 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6805889 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7515232 USD
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-753957 USD
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1.958
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3750833 shares
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
616877 shares
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5807867 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6047161 shares
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11422161 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6047161 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11422161 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
605 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1143 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11521197 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16817463 USD
CY2017 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
912962 USD
CY2018 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 USD
CY2018Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
1035847 USD
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
392 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
9711 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55944000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
59043000 USD
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
32412000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40436000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
18800000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
135000000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3102000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3321000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1877000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1941000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55900000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55944000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59043000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59000000 USD
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
53252 USD
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2800 USD
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
15702 USD
CY2017 us-gaap Depreciation
Depreciation
0 USD
CY2018 us-gaap Depreciation
Depreciation
2440 USD
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
3.56
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.57
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-18080 USD
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1843
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-78648 USD
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0002
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-2.047
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.0000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.034
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0008
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0242
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.019
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0124
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
316024 USD
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
416234 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2704853 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4655837 USD
CY2017Q4 us-gaap Goodwill
Goodwill
5200000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
5187519 USD
CY2018Q4 us-gaap Goodwill
Goodwill
0 USD
CY2017Q3 us-gaap Goodwill
Goodwill
12700000 USD
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7490886 USD
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
7500000 USD
CY2018Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5200000 USD
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
5187519 USD
CY2018Q2 us-gaap Grants Receivable
GrantsReceivable
1900000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-11503000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-16707000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-18000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-107000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11521000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16814000 USD
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3200 USD
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
837 USD
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
218267 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
151486 USD
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
534831 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-27083 USD
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
392 USD
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
9319 USD
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
33233 USD
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
193495 USD
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-193495 USD
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2800 USD
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-145223 USD
CY2017 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-662059 USD
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-253169 USD
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
113021 USD
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
91526 USD
CY2017Q4 us-gaap Liabilities
Liabilities
967045 USD
CY2018Q4 us-gaap Liabilities
Liabilities
1100767 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14259828 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7827387 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
966653 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1091056 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
155000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10111952 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9918440 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-518836 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2540128 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10268425 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10300000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-11503117 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-16738815 USD
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Operating Expenses
OperatingExpenses
11180488 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
16882312 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-11180488 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-16882312 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
289108 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
108570 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
67595 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
112943 USD
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
82810 USD
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
182660 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
193495 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
0 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
723191 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
577968 USD
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-18080 USD
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-78648 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-322629 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
143497 USD
CY2017Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
284206 USD
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
31037 USD
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
316805 USD
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11836 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
311571 USD
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
403097 USD
CY2017 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
155000 USD
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2018Q1 us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
10100000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9396 USD
CY2018 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
225000 USD
CY2018 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
224665 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
984749 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6413956 USD
CY2017 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2018 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
507000 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12230952 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29000000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28969767 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
15832 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
139348 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.72
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.21
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0185
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0252
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.46
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.03
CY2017Q1 us-gaap Share Price
SharePrice
0.18727
CY2017Q2 us-gaap Share Price
SharePrice
0.38
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2017 us-gaap Stock Issued1
StockIssued1
24279001 USD
CY2018 us-gaap Stock Issued1
StockIssued1
0 USD
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
24279001 USD
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
912963 USD
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9377717 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-710621 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
13292783 USD
CY2017Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6726620 USD
CY2017Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
846000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
924000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
65000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
78000 USD
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
55600000 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3100000 USD
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3232278 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10732421 shares
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company maintains cash balances at various financial institutions and such balances commonly exceed the </font><font style="font-family:Arial;font-size:10pt;">$250,000</font><font style="font-family:Arial;font-size:10pt;"> amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in the U.S. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant risk with respect to such cash and cash equivalents.</font></div></div>
CY2018 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Indemnifications</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As permitted under Delaware law, the Company has entered into indemnification agreements with its officers and directors that provide that the Company will indemnify the directors and officers for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by such director or officer in any action or proceeding arising out of their service as a director and/or officer. The term of the indemnification is for the officer&#8217;s or director&#8217;s lifetime. During the year ended </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;">, the Company did not experience any losses related to those indemnification obligations. The Company does not expect significant claims related to these indemnification obligations, and consequently, has concluded the fair value of the obligations is not material. Accordingly, as of </font><font style="font-family:Arial;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2017</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">no</font><font style="font-family:Arial;font-size:10pt;"> amounts have been accrued related to such indemnification provisions.</font></div></div>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:13px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the fair value of stock-based compensation, goodwill impairment and purchase accounting. Actual results could differ from those estimates and could materially affect the reported amounts of assets, liabilities and future operating results.</font></div></div>

Files In Submission

Name View Source Status
0001401914-19-000015-index-headers.html Edgar Link pending
0001401914-19-000015-index.html Edgar Link pending
0001401914-19-000015.txt Edgar Link pending
0001401914-19-000015-xbrl.zip Edgar Link pending
a1010ahammockassignment.htm Edgar Link pending
a1010b1stamtohamcklicnsagr.htm Edgar Link pending
dare-20181231.xml Edgar Link completed
dare-20181231.xsd Edgar Link pending
dare-20181231x10k.htm Edgar Link pending
dare-20181231xex211.htm Edgar Link pending
dare-20181231xex231.htm Edgar Link pending
dare-20181231xex311.htm Edgar Link pending
dare-20181231xex312.htm Edgar Link pending
dare-20181231xex321.htm Edgar Link pending
dare-20181231xex322.htm Edgar Link pending
dare-20181231_cal.xml Edgar Link unprocessable
dare-20181231_def.xml Edgar Link unprocessable
dare-20181231_lab.xml Edgar Link unprocessable
dare-20181231_pre.xml Edgar Link unprocessable
darelogohoriz2.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending